As shown in Figure 5, treatment with SI113, alone or in combination with EPO-A or VCR, yielded a modification of mRNA expression for OCT3/4, NANOG, NESTIN and OLIG2, all GBM or glioma stemness markers [28]. This evidence concerns the gene NANOG and central nervous system cancer.